Teva completed acquisition of Allergan's global generics business (Actavis Generics) for $40.5B: $33.43B in cash plus ~100M Teva shares. FTC required Teva divest 79 generic drug assets to Dr. Reddy's, Aurobindo, Cipla, Mayne, 3M, and others. Made Teva the world's largest generic pharma. Originally announced July 26, 2015; closed August 2, 2016.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Assessment window: 5yr post-close.
Key facts
AnnouncedAug 02, 2016
ClosedAug 02, 2016
Deal value$40.5B
Deal typeAcquisition/Merger
Therapeutic areaMultiple (generics)
IndicationsMultiple (generics)
Key assetsAllergan global generics portfolio (Actavis Generics)
MechanismMultiple (generic small molecules and complex generics)